The Morning That Was

The AI trade came back with force on Tuesday. After a period of choppy sentiment around semiconductor valuations and geopolitical friction, the morning session delivered a cluster of high-conviction signals that pushed chip stocks broadly higher and revived appetite for large-scale technology risk.

Broadcom (AVGO) was among the clearest beneficiaries. Apollo Global Management (APO) and Blackstone (BX) finalized a $35 billion capital solution — structured around Broadcom's AI XPV Platform — to fund a major expansion of Anthropic's compute infrastructure. Deployment is expected to begin in mid-2026. The sheer scale of the commitment, assembled through private credit and a syndicate of global banks, sent a clear signal: institutional capital is not waiting for public market confirmation before making large bets on AI infrastructure.

For Apollo and Blackstone, this is not a passive allocation. Both firms are positioning themselves as primary financiers of the AI buildout, competing directly with investment banks for mandates that would have been unthinkable for alternative asset managers a decade ago.

The Three Themes Holding the Session Together

The session's narrative rests on three distinct but reinforcing threads.

The first is private capital's acceleration into AI infrastructure. The Anthropic deal is the headline, but it reflects a structural shift: the capital requirements for frontier AI — data centers, custom silicon, networking — have outgrown what equity markets alone can supply. Private credit is filling the gap, and the $35 billion figure is a marker of how far that shift has progressed.

The second is the IPO pipeline reopening at scale. OpenAI has confidentially filed for a U.S. IPO targeting a valuation of up to $1 trillion, with a potential September debut. A confidential filing allows the company to engage regulators before making financials public — a standard mechanism for managing the process, but the reported valuation would rank among the largest U.S. listings on record. SpaceX is simultaneously preparing its own Nasdaq listing at a proposed price of $135 per share, with pre-IPO demand described as strong. Wolfe Research is separately analyzing what a SpaceX listing could mean for Tesla (TSLA) shareholders, given ongoing speculation about a potential combination between the two Elon Musk-led companies — though no deal has been announced.

The third thread is geopolitical friction hardening into market risk. The Pentagon added Alibaba (BABA), Baidu (BIDU), and BYD to its list of China military-linked companies under the so-called 1260H designation, barring direct U.S. Defense Department contracts from later this month. The designation stops short of a full trade ban but creates compliance complexity for U.S. defense contractors with existing ties to those firms — and adds a reputational overhang for institutional investors holding the names. Taiwan is separately weighing tighter AI chip export controls targeting China, a move that lifted TSMC (TSM) shares as investors read it as reinforcing the company's strategic position in Western supply chains.

Healthcare Breaks Through the Noise

Outside technology, GSK (GSK) made its largest acquisition in eight years. The British pharmaceutical group agreed to buy Nuvalent, a biotech focused on lung cancer therapies, for $10.6 billion. The deal marks a deliberate reversal: GSK had previously wound down parts of its oncology pipeline and is now rebuilding it through dealmaking at a premium price that reflects how competitive the market for late-stage cancer assets has become.

The transaction fits a broader pattern. Large pharmaceutical companies facing patent expirations on existing drugs have been aggressively acquiring smaller biotechs to replenish pipelines. At $10.6 billion, the Nuvalent deal ranks among the larger biotech acquisitions of the current cycle and signals that GSK is willing to pay up to re-enter a space it once retreated from.

The Macro Undercurrent

Not everything in Tuesday's session pointed upward. India is absorbing the consequences of what analysts are describing as a severe global oil supply disruption, with elevated crude prices widening the country's current account deficit, pressuring the rupee, and forcing growth forecasts lower. As a major energy importer, India faces asymmetric exposure when oil prices spike — the kind of macro transmission that tends to be underweighted in sessions dominated by AI deal headlines.

The oil story is a reminder that commodity markets remain a primary channel through which global stress reaches emerging market economies. The rupee's weakness and India's revised growth outlook deserve attention even as equity markets in the U.S. focus on infrastructure deals and IPO filings.

What the Afternoon Needs to Confirm

The morning session built a coherent bull case for the AI trade: massive private capital commitments, a landmark IPO filing, and geopolitical moves that — at least for TSMC — appear to reinforce rather than undermine Western semiconductor positioning. The question for the afternoon is whether that narrative holds under scrutiny.

AVGO, APO, and BX are the names most directly tied to the Anthropic deal and worth watching for any revision in how the market prices the deal's terms. BABA and BIDU face continued pressure as the Pentagon designation's practical implications become clearer to compliance teams and institutional holders.

Oracle (ORCL) remains the week's key earnings test for the AI trade in public equities. The company's stock has rallied sharply on AI optimism, and its fourth-quarter results — expected this week — will be the first major opportunity to assess whether data-center expansion and AI strategy are generating revenue growth that justifies the valuation. If the Anthropic deal represents private capital's conviction in AI infrastructure, Oracle's earnings will tell us whether public markets are pricing that conviction correctly.

The SpaceX and OpenAI IPO timelines will also draw continued scrutiny. Confidential filings and proposed listing prices are not commitments — they are opening positions in a negotiation with public market investors. The real test comes when the prospectuses are published and the roadshows begin.